Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Medarex reacquires worldwide rights to MDX-210

March 1, 1999

Immunomedics' new immunotoxin against CEA is first in its class

March 1, 1999

Corixa is first to achieve clinical testing of a microsphere-encapsulated peptide cancer vaccine

Feb. 25, 1999

Biostar initiates phase I/II trial of Norelin in prostate cancer patients and creates subsidiary

Feb. 19, 1999

Ontak available this month in U.S.

Feb. 16, 1999

Review supports hCG as a target for cancer immunotherapy

Feb. 15, 1999

Ligand purchases Marathon Biopharmaceuticals' assets

Feb. 15, 1999

PSP94 suppresses prostate cancer growth in mouse model

Feb. 12, 1999

Enrollment completed in Maxim's malginant melanoma phase III trial

Feb. 9, 1999

Ligand receives FDA approval for Ontak as CTCL treatment

Feb. 8, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
GDE4 blockade promotes remyelination, study finds
BioWorld Science
Myelin is crucial for the correct functioning of nerve signaling and its loss is a feature of neurological disorders. The cells responsible for myelination in the...